Home/Pipeline/JadiCell

JadiCell

COVID-19 ARDS

Phase I/IIStatus Unclear

Key Facts

Indication
COVID-19 ARDS
Phase
Phase I/II
Status
Status Unclear
Company

About Therapeutic Solutions International

Therapeutic Solutions International is a publicly traded biotech holding company (TSOI) with a mission to develop novel immunotherapies and regenerative medicines. Its core achievement lies in establishing a diversified portfolio of early-stage assets, primarily focused on natural killer (NK) cells and mesenchymal stem cells (MSCs), targeting cancer, neurological trauma, and inflammatory conditions. The company's strategy revolves around a capital-efficient holding structure, in-licensing promising science, and advancing programs through subsidiary entities to attract partnership capital. However, its progress is characterized by early, pre-clinical, and Phase I assets, with limited late-stage clinical validation and no commercial revenue to date.

View full company profile

About Therapeutic Solutions International

Therapeutic Solutions International is a publicly traded biotech holding company (TSOI) with a mission to develop novel immunotherapies and regenerative medicines. Its core achievement lies in establishing a diversified portfolio of early-stage assets, primarily focused on natural killer (NK) cells and mesenchymal stem cells (MSCs), targeting cancer, neurological trauma, and inflammatory conditions. The company's strategy revolves around a capital-efficient holding structure, in-licensing promising science, and advancing programs through subsidiary entities to attract partnership capital. However, its progress is characterized by early, pre-clinical, and Phase I assets, with limited late-stage clinical validation and no commercial revenue to date.

View full company profile